Hematology

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.

Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.

Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.

Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.

Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.

Policy mandates and low-burden trial designs are key to equitable stem cell transplant access, explains Karilyn Larkin, MD.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Novel combinations may improve survival in Richter transformation, a hard-to-treat condition, says Adam Kittai, MD, of Perlmutter Cancer Center.

Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

A survivor shares axi-cel therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improves QOL.

Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.

The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.

Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.